Organization | Nordic Myeloma Study Group

Nordic Myeloma Study Group Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Oslo Norway (1987)

Organization Overview

First Clinical Trial

2000

NCT00376883

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

NMSG | NMSG (Nordic Myeloma Study Group) | Nordic Myeloma Study Group | Nordic Myeloma Study Group, Germany

Active Ingredients

Drugs in Phase 3 Trials (7)

bortezomib (velcade) (5 trials)

lenalidomide (revlimid) (4 trials)

melphalan (alkeran) (2 trials)

pamidronate (aredia) (1 trial)

prednisone (meticorten) (1 trial)

thalidomide (Thalomid) (2 trials)

urea (3 trials)

Drugs in Phase 2 Trials (6)

carfilzomib (kyprolis) (2 trials)

cyclophosphamide (cytoxan) (1 trial)

dexamethasone (2 trials)

fludarabine (fludara) (1 trial)

Isatuximab (Sarclisa) (1 trial)

ixazomib (ninlaro) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Recurrence (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial APIs: 13